Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
61 hedge funds and large institutions have $25.8M invested in Zynerba Pharmaceuticals, Inc in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 13 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
5% less funds holding
Funds holding: 64 → 61 (-3)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
47% less capital invested
Capital invested by funds: $48.9M → $25.8M (-$23.1M)
59% less call options, than puts
Call options by funds: $742K | Put options by funds: $1.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.12M |
| 2 |
BlackRock
New York
|
+$393K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$392K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$266K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$236K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$4.52M |
| 2 |
RI
RTW Investments
New York
|
-$2.54M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.11M |
| 4 |
Morgan Stanley
New York
|
-$2.01M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.84M |
ZYNE Hedge Fund Activity: Q1 2018 in Review
61 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q1 2018, worth a combined $25.8M — down 47% from $48.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ZYNE and 10 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 19 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.12M. The largest seller was Mirae Asset Global Investments, exiting entirely with an estimated $4.52M sold.
- 61 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q1 2018, down from 64 in Q4 2017.
- Funds reported $25.8M of Zynerba Pharmaceuticals, Inc stock for Q1 2018, down 47% quarter-over-quarter.
- 10 funds opened new Zynerba Pharmaceuticals, Inc positions in Q1 2018 and 13 closed out, a net change of -3 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q1 2018 was Millennium Management, an estimated $1.12M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q1 2018 was Mirae Asset Global Investments, an estimated $4.52M sold.
Based on aggregated 13F filings for Q1 2018.